Pubblicazioni

Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia

2021 - NEW ENGLAND JOURNAL OF MEDICINE

Tiacci, E.; De Carolis, L.; Simonetti, E.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P. L.; Ascani, S.; Perriello, V. M.; Rigacci, L.; Gaidano, G.; Seta, R. D.; Frattarelli, N.; Falcucci, P.; Foa, R.; Visani, G.; Zaja, F.; Falini, B.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

2017 - HAEMATOLOGICA

Selleslag, Dominik; Suciu, Stefan; Meloni, Giovanna; Muus, Petra; Halkes, Constantijn J. M.; Venditti, Adriano; Ramadan, Safaa M.; Pruijt, Hans; Meert, Liv; Vignetti, Marco; Marie, Jean-Pierre; Wittnebel, SÃ©bastian; de Witte, Theo; Amadori, Sergio; Willemze, Roelof; Baron, FrÃ©dÃ©ric